Videos

Mel Mann, the longest living person who participated in the clinical trial for Gleevec – which was approved by the FDA just over 20 years ago – shares what he would tell his younger self.

Liposarcoma survivor Arianne Missimer discusses the training process for ‘American Ninja Warrior’ and how she felt the day of competition.

View the full CURE Educated Patient Lung Cancer Summit on demand.

View the full CURE Educated Patient Lung Cancer Summit on demand.

View the full CURE Educated Patient Lung Cancer Summit on demand.

More people are aware of the disparities LGBTQ patients face, but prohibitive legislature could be moving the needle backward when it comes to equality in care.

A survivor shares how she chose to approach her mindset during cancer treatments to keep herself from spiraling.

View the full CURE Educated Patient Leukemia Summit on demand.

A survivor of osteosarcoma who underwent treatment in the 1960s in a segregated hospital ward, shares how he was able to find strength during that time.

CURE spoke with Dr. Rajiit Rampal, on behalf of the MPN Research Foundation, about MPN symptoms and their management.

CURE spoke with Brandon Goetzman, board member from the MPN Research Foundation, on elevating the patient’s voice when it comes to their care for myeloproliferative neoplasms.

CURE spoke with Dr. Gabriela Hobbs, on behalf of the MPN Research Foundation, about the need for clinical trial education for patients with myeloproliferative neoplasms.

CURE spoke with Dr. Rajiit Rampal, on behalf of the MPN Research Foundation, about disease progression in myeloproliferative neoplasms.

CURE spoke with Dr. Gabriela Hobbs, on behalf of the MPN Research Foundation, about currently available treatment options, as well as those under clinical investigation, for patients with myeloproliferative neoplasms.

Rob Paulsen is the voice behind many beloved cartoon characters, but after receiving a cancer diagnosis, he discovered a whole new way to relate to others.

Online resources available to patients with lung or thyroid cancer who are considering participation in a clinical trial after undergoing comprehensive genomic profiling.

The pros and cons of conducting pathology assessments for comprehensive biomarker tests in central laboratories versus local laboratories.

Dr Thomas E. Hutson comments on the rationale for using combination immune therapy, as well as a combination of immune therapy and an oral VEGF inhibitor for initial treatment of RCC.

Kidney cancer expert, Dr Thomas E. Hutson, shares insight on managing adverse events resulting from combination therapy in RCC.

An expert discusses the most common reasons his patients ask him about medical marijuana.

Current barriers that impact patient access to comprehensive biomarker testing in the community and efforts underway to help advocate for increased accessibility to molecular assays moving forward.

Resources available to support patients and community oncologists who are interested in learning more and gaining access to comprehensive biomarker testing.

The vaccine immune response monitoring platform can identify weak responses in patients with cancer and help determine the potential need for a booster shot.

Thomas E. Hutson, DO, PharmD, discusses his approach to determining the optimal initial therapy for a patient with RCC.

Urologic oncology expert, Dr Thomas E. Hutson, reviews additional agents and clinical trials in the pipeline for the treatment of RCC.

View the full CURE® Educated Patient® Webinar: Gastrointestinal Stromal Tumor (GIST).

Cancer patients, Deborah and George, reflect on their emotions while waiting to receive back results from biomarker testing and explain what it was like processing the information delivered by their test results as presented by their oncologists.

George Labonte explains what it was like receiving a diagnosis of medullary thyroid cancer and describes his experience being recommended for biomarker testing and concerns surrounding testing for germline mutations.

An expert in kidney cancer reviews the phase 3 CLEAR trial for frontline metastatic renal cell carcinoma.

Dr Thomas E. Hutson shares insight on recent advances for the treatment of RCC including the role of and VEGF inhibitors, immune therapy, and mTOR inhibitors.